Business Context and Reporting Period
This Form 8-K is filed by Salarius Pharmaceuticals, Inc. (not Decoy Therapeutics Inc.) on January 21, 2021, reporting an event that occurred on January 19, 2021. The filing addresses the company's compliance status with the Nasdaq Stock Market.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The only financial metric referenced is the stock price:
- Stock Price: The closing bid price of the Company's common stock was at or above $1.00 per share for the last 10 consecutive business days (January 4 to January 15, 2021).
Material Changes
The material change reported is the resolution of a listing deficiency:
- The Nasdaq Listing Qualifications Department confirmed that Salarius Pharmaceuticals regained compliance with Nasdaq Listing Rule 5550(a)(2) (Minimum Bid Price Requirement).
- The matter regarding the company's listing status is now closed.
Guidance, Outlook, and Risks
The filing contains no management guidance, forward-looking outlook, or discussion of risks and contingencies beyond the resolution of the specific listing compliance issue. No unusual items were reported.
Investor Verification Checklist
- Verify the current trading status of Salarius Pharmaceuticals (Ticker: SLRX) on the Nasdaq Capital Market.
- Confirm the company's continued compliance with Nasdaq minimum bid price requirements in subsequent periods.
- Note that this filing is a regulatory compliance update and does not reflect operational or financial performance changes.